StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
300109.SZ$17.48-0.79%
Fair $17.48+0.0%

300109.SZ

Boai NKY Medical Holdings Ltd.

Basic Materials / Specialty ChemicalsShenzhen

$17.48

-0.14 (-0.79%)

Fairly Valued+0.0%Fair Value $17.48Fund rank 27/100 · Data gapFallback financials|
SA 38/D
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $110.4M · quality 46.0/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 16/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

38/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific holding-company NAV/SOTP model required: targets are disabled until look-through holdings, debt and discount data exists.
Thesis & Journal · 300109.SZLocal privado en este navegador · Boai NKY Medical Holdings Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$8.4B

P/E

49.9x

↑

EV/EBITDA

23.0x

↑

ROE

5.2%

↑

Gross Margin

45.8%

↑

Debt/Equity

0.09

↓
52-Week Range$17
$16$21

TradingView lightweight chart

300109.SZ price, volumen y niveles de valoración

Último $17.48Periodo +3.7%
Fair value: $17.48

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-7.4%

FCF CAGR

—

FCF margin

10.0%

FCF / Net income

0.62x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.18B · net income $190.1M · FCF $117.7M

2022-FY → 2025-FY

Gross margin

45.8%-0.7% pts

Operating margin

25.2%-4.1% pts

Net margin

16.1%-3.5% pts

FCF margin

10.0%+10.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.18B$1.18B$1.61B$1.58B$1.49B
Net Income$190.1M$190.1M$349.7M$493.0M$291.5M
EBITDA$354.4M$354.4M$510.4M$661.6M$453.0M
EPS0.390.390.721.020.57
Gross Margin45.8%45.8%46.9%56.5%46.5%
Operating Margin25.2%25.2%29.2%37.2%29.3%
Net Margin16.1%16.1%21.8%31.1%19.6%
Balance Sheet
Debt/Equity0.090.090.120.020.02
Current Ratio3.213.21———
Cash Flow
Free Cash Flow$117.7M$117.7M$-18.7M$110.4M$-14.2M
Returns
ROE5.2%5.2%9.6%13.9%9.3%
Valuation
P/E49.9449.9420.0417.1944.03
EV/EBITDA23.0223.0213.5412.4627.28
P/B2.312.311.932.394.09
Growth & Yield
Revenue Growth-26.7%-26.7%1.4%6.6%—
EPS Growth-45.8%-45.8%-29.4%80.0%—
Dividend Yield1.4%1.4%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

58.4%

muy exigente

EPS terminal req.

$1.55

Spread vs growth

-104.3%

5Y implied EPS CAGR

36.9%

muy exigente

EPS terminal req.

$1.88

Spread vs growth

-82.8%

10Y implied EPS CAGR

22.7%

exigente

EPS terminal req.

$3.02

Spread vs growth

-68.6%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +7.6%

Total return

+7.6%

Start / end P/E

22.9x → 44.8x

EPS bridge

0.72 → 0.39

Residual

-44.0%

EPS growth-45.8%
Multiple rerating+96.1%
Dividend+1.4%
Residual / FX / buybacks / cross-term-44.0%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.